Drug news
UK will fund Sovaldi for patients with acute liver failure or those awaiting transplantation - Gilead
The NHS England's Clinical Priorities Advisory Group (CPAG) has recommended that around 500 patients who have acute liver failure, and/or are awaiting liver transplantation, will be funded to access Gilead's Sovaldi (sofosbuvir) from Gilead. Although not yet NICE approved Sovaldi will be made available in the UK for patients who at significant risk of mortality or who require transplantation. NICE is currently appraising Sovaldi, and is expected to give its initial judgement in May 2014.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.